Review on Diabetes Mellitus Type-2

Authors

  • Tholla Bhagyamma Department of Pharmacology, Sri Padmavathi School of Pharmacy, Tiruchanoor, Tirupati-517503, Andhra Pradesh, India https://orcid.org/0000-0001-5820-1823
  • Kishore Bandarapalle Department of Pharmaceutics, Sri Padmavathi School of Pharmacy, Tiruchanoor, Tirupati-517503, Andhra Pradesh, India https://orcid.org/0000-0003-0032-4331
  • Dondapati Tejaswi Department of Pharmaceutics, Sri Padmavathi School of Pharmacy, Tiruchanoor, Tirupati-517503, Andhra Pradesh, India https://orcid.org/0000-0002-1520-5303
  • Kammapalli Ganesh Department of Pharmacology, Sri Padmavathi School of Pharmacy, Tiruchanoor, Tirupati-517503, Andhra Pradesh, India https://orcid.org/0000-0001-6976-1594
  • Bandi Haripriya Department of Pharmacology, Sri Padmavathi School of Pharmacy, Tiruchanoor, Tirupati-517503, Andhra Pradesh, India
  • Kokkarla Vyshnavi Department of Pharmacology, Sri Padmavathi School of Pharmacy, Tiruchanoor, Tirupati-517503, Andhra Pradesh, India

DOI:

https://doi.org/10.26452/fjphs.v3i1.339

Abstract

Type 2 diabetes mellitus is a metabolic disorder that is becoming more and more common everywhere in Diabetes mellitus. Due to an ageing population, it was anticipated that the number of impacted persons will triple in the following ten years, placing further strain on healthcare professionals, especially in developing nations. In many nations around the world, this tendency is quickly spreading like an epidemic. The World Health Organization (WHO) and American Diabetes Association (ADA) protocols, which take into account clinical and laboratory factors, continue to serve as the basis for diagnosis and screening. Attempting to alter one's way of life, managing obesity, using oral antihyperglycemic drugs, as well as using insulin additives like metformin, a biguanide which reduces insulin resistance and is still the medicine of choice, are all recommended. Alpha-glucosidase inhibitors, insulin, phenothiazines, or non-sulfonylurea secretagogues are additional effective medications. Recent research into the pathophysiology of type 2 diabetes has resulted in the development of novel medications, including glucagon-like peptide one analogous drugs, dipeptidyl peptidase-IV inhibitors, sodium-glucose cotransporter two and 11ß-hydroxysteroid dehydrogenase 1 inhibitors, insulin-releasing glucokinase activators, and pancreatic-G-protein-coupled fatty acid-receptor inhibitors agonist, despite having a license to use it since 2006, inhaled insulin has been taken off the market due to little demand.

Keywords:

Diabetes Mellitus Type 2, Diagnosis, Treatment, Newer Medications

Downloads

Download data is not yet available.

Published

2023-01-04

How to Cite

Tholla Bhagyamma, Kishore Bandarapalle, Dondapati Tejaswi, Kammapalli Ganesh, Bandi Haripriya, & Kokkarla Vyshnavi. (2023). Review on Diabetes Mellitus Type-2. Future Journal of Pharmaceuticals and Health Sciences, 3(1), 46–51. https://doi.org/10.26452/fjphs.v3i1.339

Issue

Section

Review Articles

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)